Annovis Bio Inc. Common Stock (ANVS)
Stock · NYSE · Health Care
$1as of 10/16/2026
Price chart
Active signals
ANVS Signal Track Record
How signals performed across all stocks →What ANVS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 41 | -8.7% | 46% | September 3, 2026 |
| Bollinger Band BreakdownActive now | 21 | -2.0% | 48% | September 3, 2026 |
| Bollinger Band Breakout | 20 | -11.5% | 35% | July 6, 2026 |
| 200-Day Moving Average TouchActive now | 15 | -7.0% | 27% | March 17, 2026 |
| Any 20-session window (baseline) | -5.5% | 37% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ANVS
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and A…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 7
- Website
- www.annovisbio.com/
Fundamentals
- 1-day range
- $0.987$1.08
- Market cap
- $64.44M
- P/E (trailing)
- —
- P/E (forward)
- -1.16
- EPS (trailing)
- $-1.78
- Dividend yield
- —
- Beta
- 1.31
- Avg. volume
- 862.6K
Forecasts
4 analyst ratings
Annovis Bio Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ANVSAnnovis Bio Inc. Common Stock$0.99▼ 5.71%Market cap $64.44MP/E —$1.01$5.5
- PLRXPliant Therapeutics Inc. Common Stock$0.9▼ 7.41%Market cap $65.02MP/E —$0.8838$1.95
- BOLDBoundless Bio Inc. Common Stock$2.34▼ 0.43%Market cap $63.80MP/E —$0.9612$3.16
- PMVPPMV Pharmaceuticals Inc. Common Stock$1.21▼ 6.20%Market cap $62.93MP/E —$1.02$1.91
- MNOVMedicinova Inc Common Stock$1.42▼ 2.07%Market cap $66.94MP/E —$1.17$3.9
- RNTXRein Therapeutics Inc. Common Stock$0.59▼ 6.05%Market cap $67.45MP/E —$0.5401$2.18
- CINGCingulate Inc. Common Stock$4.36▼ 0.68%Market cap $68.02MP/E —$3.16$11.89
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ANVS Annovis Bio Inc. Common Stock | $64.44M | — | $0.99 | ▼ 5.71% | $1.01$5.5 |
| PLRX Pliant Therapeutics Inc. Common Stock | $65.02M | — | $0.9 | ▼ 7.41% | $0.8838$1.95 |
| BOLD Boundless Bio Inc. Common Stock | $63.80M | — | $2.34 | ▼ 0.43% | $0.9612$3.16 |
| PMVP PMV Pharmaceuticals Inc. Common Stock | $62.93M | — | $1.21 | ▼ 6.20% | $1.02$1.91 |
| MNOV Medicinova Inc Common Stock | $66.94M | — | $1.42 | ▼ 2.07% | $1.17$3.9 |
| RNTX Rein Therapeutics Inc. Common Stock | $67.45M | — | $0.59 | ▼ 6.05% | $0.5401$2.18 |
| CING Cingulate Inc. Common Stock | $68.02M | — | $4.36 | ▼ 0.68% | $3.16$11.89 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Hoffman Michael B · May 20, 2026 · Buy18.8K @ $1.8
- Hoffman Michael B · May 20, 2026 · Buy2.6K @ $1.75
- Hoffman Michael B · May 20, 2026 · Buy54.9K @ $1.9
Institutional Ownership
March 31, 2026
- Total shares held
- 5.09M
- Total value held
- $11.09M
- Institutional holders
- 55
- Unknown1.19M
- Unknown872.4K
- Unknown627.7K
- Unknown541.0K
- Unknown347.6K
- Unknown247.5K
- Unknown141.7K
- Unknown139.5K
- Unknown104.9K
- Unknown86.7K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Annovis Bio Partners with Weave Bio for Alzheimer's NDA
Annovis Bio has announced a partnership with Weave Bio to use an AI regulatory platform. This collaboration is aimed at preparing the New Drug Application for buntanetap, a treatment for Alzheimer’s disease. The move supports the company's efforts to advance its lead candidate through the regulatory process.
Annovis Bio Partners with Weave Bio for Alzheimer's NDA. Annovis Bio has announced a partnership with Weave Bio to use an AI regulatory platform. This collaboration is aimed at preparing the New Drug Application for buntanetap, a treatment for Alzheimer’s disease. The move supports the company's efforts to advance its lead candidate through the regulatory process.